Cumberland Pharmaceuticals Reports $77.8M Q3 Net Income
Cumberland said Q3 2026 net income included a gain on divested assets. It also plans to submit an NDA for ifetroban in DMD after the FDA granted rolling review, and announced Phase 2 systemic sclerosis results.
Cumberland reported Q3 2026 net income of $77.8M, including a gain on divested assets. It plans to submit an NDA for ifetroban in DMD after the FDA granted rolling review; Phase 2 systemic sclerosis results were also announced.Material DetailsContext by AI AnalystThis is an early-stage transition t…